Evidence map›Paper›PMID 30465158›Full record

ArticleBreast cancer research and treatment2019

Metabolic syndrome and risk of breast cancer mortality by menopause, obesity, and subtype.

Daniel T Dibaba, Kemi Ogunsina, Dejana Braithwaite, Tomi Akinyemiju

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 4 pooled it
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 4 syntheses or guidelines pooled it, 109 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Effect of Metformin on Breast Density in Overweight/Obese Premenopausal Women.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021
    Trial
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Observational
  14. Observational
  15. Review
  16. Metabolic Syndrome and Risks of Breast Cancer Outcomes for Luminal, Triple-Negative, and HER2-Overexpressing Subtypes.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Daniel T DibabaDepartment of Epidemiology, University of Kentucky, Lexington, KY, USA.
Kemi OgunsinaDepartment of Public Health Sciences, University of Miami, Miami, FL, USA.
Dejana BraithwaiteDepartment of Oncology, Georgetown University, Washington, DC, USA.
Tomi AkinyemijuDepartment of Epidemiology, University of Kentucky, Lexington, KY, USA. tomiakin@uky.edu.ORCID http://orcid.org/0000-0002-1412-3234
University of Kentucky · USGeorgetown University · USUniversity of Miami · US

Funding

Metabolic Syndrome and Epigenetic Markers of Breast Cancer in Nigerian WomenK01TW010271 · FIC · UNIVERSITY OF KENTUCKY · PI AKINYEMIJU, TOMI F · 2016 to 2020
$676k
FIC NIH HHS K01 TW010271National Institutes of Health (US) K01TW010271
6 · The paper itself

Abstract

purposeTo investigate the association between metabolic syndrome (MetS) and risk of breast cancer mortality by menopausal status, obesity, and subtype.

methodsData from 94,555 women free of cancer at baseline in the National Institute of Health-American Association of Retired Persons Diet and Health Study cohort (NIH-AARP) were used to investigate the prospective associations of baseline MetS and components with risk of breast cancer mortality using Cox proportional hazard regression models adjusted for baseline behavioral and demographic covariates.

resultsDuring a mean follow-up duration of 14 years, 607 women in the cohort died of breast cancer. Overall, MetS was associated with a 73% increased risk of breast cancer mortality (HR 1.73; 95% CI 1.09-2.75); the association remained significant among post-menopausal women overall (HR 2.07, 95% CI 1.32, 3.25), and among those with overweight/obesity (HR 1.15, 95% CI 0.81, 1.64). MetS was associated with increased risk of breast cancer mortality for ER+/PR+ (HR 1.28, 95% CI 0.52, 3.16) and lower risk for ER-/PR- (HR 0.44, 95% CI 0.11, 1.75) subtypes; however, the associations were not statistically significant. Of the individual MetS components, high waist circumference (HR 1.32, 95% CI 1.03, 1.70), high cholesterol (HR 1.24, 95% CI 1.05, 1.46), and hypertension (HR 1.24, 95% CI 1.05, 1.46) were independently associated with increased risk of breast cancer mortality.

conclusionsMetS was associated with increased risk of breast cancer mortality, especially among post-menopausal women. Further studies with larger sample sizes are needed to definitively determine the extent to which these associations vary by breast cancer subtype.

Indexed as

AgedBreast NeoplasmsFemaleHumansMenopauseMetabolic SyndromeMiddle AgedObesityRisk FactorsBreast cancer mortalityHormone-receptor subtypesMenopauseMetabolic syndromeObesity

Identifiers

PMID30465158
PMCPMC6461393
OpenAlexW2901247168

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.